Switzerland remains one of the densest MedTech ecosystems in Europe, but since the MRA with the EU lapsed in 2021, Swiss manufacturers are treated as third-country manufacturers under MDR. That means extra regulatory burden — and Swiss funding must cover it. Innosuisse, cantonal programmes, and foundation grants form the core non-dilutive stack.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • Since the EU-Switzerland Mutual Recognition Agreement (MRA) for medical devices lapsed in May 2021, Swiss MedTech manufacturers are treated as third-country manufacturers under MDR.
  • This adds a real cost layer: an EU-based Authorised Representative, updated labelling, and additional compliance work to place devices on the EU market.
  • Swiss non-dilutive funding — Innosuisse, cantonal programmes, and foundations — has to fund the core R&D plus the third-country regulatory overhead.
  • Innosuisse is the primary federal innovation agency and funds collaborative innovation projects between companies and research institutions.
  • Cantonal programmes vary widely; Zurich, Vaud, and Basel have the richest MedTech-relevant instruments.
  • Budget planning must explicitly include the EU AR relationship and the additional documentation burden from day one.

Why Swiss MedTech funding is a special case

Switzerland has a MedTech density that few countries in the world can match. Basel, Zurich, Lausanne, Bern, and the Jura arc host some of the largest MedTech manufacturers in Europe and a long tail of specialised suppliers. The research base is world-class — ETH Zurich, EPFL, the university hospitals. The capital is patient. The talent pool is deep. On paper, Switzerland is as good a place to start a MedTech company as exists.

Then came 2021. The Mutual Recognition Agreement (MRA) between Switzerland and the EU, which had covered medical devices, was not updated to align with the MDR. On 26 May 2021, when the MDR became fully applicable, Switzerland effectively moved from "EU-aligned" to "third country" status for medical devices. Swiss manufacturers placing devices on the EU market now fall under the same rules that apply to manufacturers based in the US or Japan.

For a founder, this is not a footnote. It is a budget line. It is a labelling change. It is an additional contractual relationship with an EU-based Authorised Representative. It is a material increase in the cost of doing MedTech business in Switzerland for the EU market — and Swiss funding instruments are where you cover that increase.

What MDR actually says about third-country manufacturers

The relevant provisions for a Swiss manufacturer are MDR Article 10 (manufacturer obligations) and MDR Article 11 (Authorised Representative). MDR Article 11 requires that a manufacturer not established in a Member State, who places a device on the Union market, must designate a single Authorised Representative established in the Union. The AR takes on specific responsibilities defined in Article 11(3), including verifying that the EU declaration of conformity and technical documentation have been drawn up and, where applicable, that an appropriate conformity assessment procedure has been carried out.

In practical terms for a Swiss startup: you need an EU AR. Your labelling must carry the EU AR details. Your contracts must reflect the AR relationship. Your PRRC and your AR's PRRC must function as a coherent regulatory function, not two disconnected roles. Swiss-specific rules also require a Swiss Authorised Representative (CH-REP) for the Swiss domestic market.

The money implication: a Swiss MedTech startup has a structurally higher regulatory cost base than an equivalent German or Austrian startup. Non-dilutive funding in Switzerland exists in part to keep Swiss MedTech competitive despite that structural disadvantage.

The three layers of Swiss non-dilutive funding

Layer 1 — Innosuisse (federal)

Innosuisse is the Swiss Innovation Agency. For MedTech startups, Innosuisse instruments typically cluster around:

  • Innovation projects — collaborative projects between a company and a research institution (typically ETH, EPFL, a university, or a university of applied sciences). The research partner is normally funded directly by Innosuisse for its part of the work, while the company contributes its own resources.
  • Startup coaching and support — non-financial support including coaching, training, and international programmes for Swiss startups.
  • Early-stage instruments — various programmes targeting science-based startups at the earliest stages.

The core Innosuisse innovation project mechanism is particularly well-suited to MedTech because it funds the collaboration between a company and a research institution — exactly the collaboration pattern that MedTech early-stage work typically needs (clinical partners, usability research, bench testing with academic labs).

Layer 2 — Cantonal programmes

Each canton runs its own economic development and innovation programmes. Three clusters matter most for MedTech:

  • Zurich — deep MedTech ecosystem around ETH and the university hospital, with cantonal and city-level innovation instruments.
  • Vaud and Geneva (Lake Geneva region) — EPFL, CHUV, and a strong MedTech and biotech cluster, with cantonal programmes and regional instruments.
  • Basel — historically pharma-dominated but with MedTech activity and cantonal support.

Other cantons (Bern, St. Gallen, Ticino, Jura, Neuchâtel) also run MedTech-relevant programmes, particularly around microtechnology and precision instruments in the Jura arc.

Layer 3 — Foundations and prizes

Switzerland has an unusually active foundation landscape. Several large private foundations fund early-stage MedTech research and company formation. Science-based startup prizes and competitions (Venture Kick, W.A. de Vigier, >>venture>>) regularly include MedTech winners and provide non-dilutive capital at critical early stages.

A worked example: funding the third-country reality

Consider a Lausanne-based team spinning out of EPFL with a Class IIa active therapeutic device. Their 30-month pre-Series-A plan looks roughly like this (illustrative numbers, verify current caps):

  • Innosuisse innovation project — collaborative project with the EPFL lab that originated the technology, covering about 18 months of shared R&D. Research partner funded directly; the company absorbs its own staff and materials costs.
  • Cantonal innovation support — Vaud-level instrument covering part of the early prototyping and pre-clinical testing.
  • Venture Kick or equivalent — prize money supporting company formation and early operations.
  • Foundation grant — targeted to the specific clinical area.

On top of this stack, they carry a dedicated budget line for:

  • EU Authorised Representative fees — annual contract with an EU-based AR, typically structured as a setup fee plus recurring fees.
  • CH-REP coverage — Swiss Authorised Representative arrangement for the domestic Swiss market.
  • Dual labelling work — artwork, translation, and documentation for both EU and Swiss markets.
  • Additional regulatory affairs hours — for the coordination overhead that third-country status imposes.

The team that plans for this third-country overhead from day one ships. The team that discovers it in month 15 has a budget crisis.

The Subtract to Ship playbook for Swiss non-dilutive funding

Step 1 — Budget the third-country overhead before you raise. Put EU AR costs, CH-REP costs, and dual-labelling costs into the runway calculation explicitly. Do not hide them inside "regulatory miscellaneous."

Step 2 — Build your Innosuisse research partnership early. The innovation project mechanism rewards teams that already have a credible research partner with a track record. Pick the partner before writing the grant.

Step 3 — Pick your canton deliberately. Canton-level instruments are significant and vary widely. The right canton for a neurotech device is not the right canton for an orthopaedic implant.

Step 4 — Map work packages to MDR deliverables. Even though Switzerland is a third country under MDR, any credible grant application will show evaluators that the team understands the EU regulatory path. Classification under MDR Annex VIII, QMS plan per EN ISO 13485:2016+A11:2021, risk management per EN ISO 14971:2019+A11:2021 — these are the deliverables that make work packages credible.

Step 5 — Stack the foundation and prize layer. Venture Kick and the foundation circuit can add real non-dilutive capital at early stages. These are not core funding, but they compound — and the prestige opens doors with Innosuisse and cantonal evaluators.

Step 6 — Appoint your EU AR contractually before your first EU shipment, not after. The AR relationship must exist before the device is placed on the Union market. A grant timeline that assumes AR appointment "later" is a grant timeline that will collide with reality.

Step 7 — Treat CH-REP and EU AR as a coordinated function. Both relationships need to work together on vigilance, PMS, and documentation. Swiss founders who treat the two markets as completely separate regulatory universes create coordination problems that a good regulatory advisor would have prevented.

Reality Check

  1. Have you explicitly budgeted the cost of an EU Authorised Representative into your runway?
  2. Do you understand that Switzerland has been a third country under MDR since the MRA lapsed in May 2021?
  3. Do you have a credible Swiss research partner (ETH, EPFL, university, UAS, or university hospital) for an Innosuisse innovation project?
  4. Have you picked your canton deliberately, based on which cantonal programmes fit your device category?
  5. Can you state your MDR device class under Annex VIII and your conformity assessment route?
  6. Do your grant work packages reference specific MDR deliverables — QMS, risk management, technical documentation?
  7. Have you identified a CH-REP arrangement for the domestic Swiss market?
  8. Do your EU AR and CH-REP plans actually coordinate on vigilance and PMS, or are they two disconnected contracts?

Frequently Asked Questions

Is Switzerland still part of the EU MDR system? No. The Mutual Recognition Agreement that previously made Switzerland effectively part of the EU single market for medical devices lapsed in May 2021. Swiss manufacturers are treated as third-country manufacturers under MDR for the purposes of placing devices on the EU market, meaning an EU-based Authorised Representative is required under Article 11.

Do Swiss startups need both an EU AR and a CH-REP? Yes, if they sell in both the EU and Switzerland. The EU AR is required by MDR Article 11 for access to the EU market. A Swiss Authorised Representative is required by Swiss domestic rules for access to the Swiss market. These are two distinct roles under different legal instruments.

Can Swiss startups access EU Horizon Europe funding? Swiss participation in Horizon Europe has gone through several political phases since 2021. . Check the current status before building your stack around it.

How much does an EU Authorised Representative cost? The market varies widely depending on device class, complexity, and service level. Plan on a setup fee plus annual recurring fees, and treat it as a contractual relationship, not a one-off purchase. Cheap AR arrangements often come with thin support and become a liability during Notified Body audits.

Does Innosuisse fund the company directly? The Innosuisse innovation project mechanism typically funds the research partner directly for their share of the work, with the company contributing its own resources. This is different from direct grant mechanisms in some other countries. Check the current rules on company-side funding before planning your cashflow.

Can Swiss MedTech startups still CE-mark their devices? Yes. Swiss manufacturers can still obtain CE marking under MDR by working with an EU-based Notified Body and designating an EU Authorised Representative. The process is the same as for any other third-country manufacturer — it is just more administratively demanding than it was before May 2021.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 10, Article 11, Annex VIII.
  2. EN ISO 13485:2016+A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes.
  3. EN ISO 14971:2019+A11:2021 — Medical devices — Application of risk management to medical devices.